<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148356</url>
  </required_header>
  <id_info>
    <org_study_id>640-0047</org_study_id>
    <nct_id>NCT00148356</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries</brief_title>
  <acronym>ZoMaxx™ I</acronym>
  <official_title>A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx&#xD;
      drug-eluting stent in patients with blockage of native coronary arteries. The study is&#xD;
      designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that&#xD;
      has proven superior to bare metal stents and is a recognized standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart disease is the leading cause of death in Europe as a whole, and while mortality rates&#xD;
      for cardiovascular disease have decreased in most western European countries, due to expanded&#xD;
      use of prevention strategies and better treatment, coronary heart disease mortality in the&#xD;
      middle age groups is increasing rapidly in most of the countries in Eastern Europe. The&#xD;
      number of procedures performed to treat cardiovascular disease in Europe is constantly&#xD;
      increasing, although different types of procedures are exhibiting different trends.&#xD;
      Percutaneous coronary interventions (PCI) procedures, for example, totaled 430,000 in the&#xD;
      European Union (15 countries) and 520,000 in Europe as a whole (33 countries) in 2000, as&#xD;
      reported by the Euro Heart Survey, and growth is continuing at a rate of more than 20% per&#xD;
      year. Despite the effectiveness of intracoronary stents in maintaining a larger luminal&#xD;
      diameter as compared to angioplasty alone, 15 - 35% of in-stent restenosis occurs within 6 to&#xD;
      9 months after stent placement. While stents can reduce restenosis by blocking vascular&#xD;
      recoil and remodeling, mechanical intervention alone is incapable of treating the biological&#xD;
      problem of neointimal hyperplasia. Various approaches have been used to treat in-stent&#xD;
      restenosis, including balloon angioplasty, repeat stenting, rotational and directional&#xD;
      atherectomy, laser and local use of radiation at the time of stenting (brachytherapy).&#xD;
      However, these techniques add complexity to the interventional procedure and have not had&#xD;
      documented success in preventing restenosis. Drug-eluting stents (DES) using&#xD;
      antiproliferative agents delivered via a polymer based stent platform have shown significant&#xD;
      success in the reduction of restenosis in de novo lesions over the traditional bare metal&#xD;
      stents in randomized clinical trials. Local delivery of the pharmacological agent allows for&#xD;
      controlled delivery of high drug concentrations to the targeted tissue while maximizing&#xD;
      systemic drug effects. The ZoMaxx I Trial is a study of the ZoMaxx Drug Eluting Coronary&#xD;
      Stent System (ZoMaxx DES) to evaluate the potential benefits of the local application of the&#xD;
      zotarolimus drug in combination with a phosphorylcholine (PC)-coated tri-metal stent.&#xD;
&#xD;
      ZoMaxx™ Drug-Eluting Stent System is an Investigational device. Limited by Federal (U.S.) law&#xD;
      to investigational use only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point is in-segment late-loss at 9 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion revascularization(TLR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>at 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events(MACE) defined as Cardiac Death, MI( Q-wave and non Q-wave) or TVR</measure>
    <time_frame>at 30 days, 6,9,12 months and anually through 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZoMaxx™ Drug-Eluting Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ZoMaxx™ Drug-Eluting Coronary Stent System</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include all of the following:&#xD;
&#xD;
          -  Subject is ≥ 18 years old.&#xD;
&#xD;
          -  Female of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to enrollment and utilize reliable birth control for nine (9) months after&#xD;
             enrollment.&#xD;
&#xD;
          -  Subject is eligible for percutaneous coronary intervention (PCI) and has a single&#xD;
             lesion requiring treatment.&#xD;
&#xD;
          -  Subject is an acceptable candidate for CABG.&#xD;
&#xD;
          -  Subject has clinical evidence of ischemic heart disease or a positive functional&#xD;
             study.&#xD;
&#xD;
          -  Subject has documented stable angina pectoris&#xD;
&#xD;
        Exclusion Criteria include all of the following:&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction (AMI) or CK-MB &gt; 2x upper limit of normal&#xD;
             within 72 hours of the intended treatment (refer to WHO definition).&#xD;
&#xD;
          -  Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or&#xD;
             ticlopidine (Ticlid®), heparin, stainless steel, tantalum, contrast agent (that cannot&#xD;
             be adequately premedicated), paclitaxel, or drugs similar to ABT-578 (i.e. tacrolimus,&#xD;
             sirolimus, everolimus).&#xD;
&#xD;
          -  A platelet count &lt; 100 x 109/L or &gt; 700 x 109/L (&lt; 100,000 cells/mm3 or &gt; 700,000&#xD;
             cells/mm3); a WBC &lt; 3,000 cells/mm3; or a hemoglobin &lt; 10.0 g/dl.&#xD;
&#xD;
          -  Acute or chronic renal dysfunction (creatinine &gt; 2.0 mg/dl or &gt; 150 µmol/L).&#xD;
&#xD;
          -  Subject has had any previous or planned brachytherapy in the target vessel.&#xD;
&#xD;
          -  Target vessel has evidence of thrombus or is excessively tortuous (&gt; 60 degree bend)&#xD;
             that makes it unsuitable for proper stent delivery and deployment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Chevalier, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Cardiologique du Nord</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Victoria</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middelheim Algemeen Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KU Leuven - UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet / University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Århus</city>
        <zip>Aarhus N</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <zip>83190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardilogique du Nord, 32-36, rue des Moulins Gémeaux</name>
      <address>
        <city>Saint-Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil - CHU</name>
      <address>
        <city>Toulouse, Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Gatien</name>
      <address>
        <city>Tours</city>
        <zip>37042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Johannes Krankenhaus</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Practice and Hospital Prof. Silber</name>
      <address>
        <city>Munich</city>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Siegburg GmbH</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <zip>2790-134</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bodensee</name>
      <address>
        <city>Kreuzlingen</city>
        <zip>8280</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Tour Hospital</name>
      <address>
        <city>Meyrin-Geneva</city>
        <zip>1217</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW36NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010.</citation>
    <PMID>19463354</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Abbott Vascular</name_title>
    <organization>Abbott Vascular</organization>
  </responsible_party>
  <keyword>drug eluting stents</keyword>
  <keyword>stents</keyword>
  <keyword>angioplasty</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>total coronary occlusion</keyword>
  <keyword>coronary artery restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>vascular disease</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>coronary artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

